Although homologous recombination (HR) is considered a potentially error-free pathway, cells lacking critical HR genes, such as the major hereditary breast/ovarian cancer predisposition genes, BRCA1 or BRCA2, frequently engage error-prone homologous recombination mechanisms in which HR termination does not occur in a timely fashion. Here, BRCA2 is linked to ovarian cancer.